Krishnan predicts no FDA-style AI regulator under Trump
Is this a scandal?
No longer — the story has resolved. Noise 7/100, holding steady, across 0 sources.
Expect executive orders reinforcing sectoral oversight because the administration prioritizes removing barriers to domestic compute scaling over harmonizing with international safety standards.
Noise 7/100 — louder than 98% of tracked AI controversies.
Why it matters
Signals a definitive US shift toward deregulation, diverging from EU-style compliance frameworks and reshaping global AI governance norms.
Key points
- Sriram Krishnan explicitly ruled out creating a centralized FDA-style pre-market approval agency for AI models.
- Krishnan attributed negative public sentiment partly to alarmist rhetoric from AI safety researchers and industry insiders.
- The Trump administration favors sector-specific guidance over horizontal licensing to maintain geopolitical competitiveness.
- This stance formally rejects proposals for mandatory safety certifications advocated by some leading AI labs.
- The policy divergence from the EU AI Act creates potential friction for companies operating in both jurisdictions.
The story
Sriram Krishnan, a senior technology policy advisor to the Trump administration, stated in a Financial Times interview that the United States will not establish an FDA-equivalent regulatory body for artificial intelligence. Krishnan attributed current public skepticism toward AI partly to what he characterized as excessive "doomer" messaging from within the tech industry itself. He argued that heavy-handed pre-market approval processes would stifle American innovation and cede strategic advantage to geopolitical rivals. The remarks clarify the administration's intent to pursue sector-specific oversight rather than comprehensive horizontal regulation. This position contrasts sharply with the European Union’s AI Act, which mandates rigorous risk assessments for high-stakes systems. Industry stakeholders have reacted with divided opinions regarding the long-term safety implications of this deregulatory approach. Krishnan’s comments represent the most explicit rejection of centralized AI safety licensing by a current US policymaker.
Who's involved
Warn that lacking pre-deployment evaluation standards increases catastrophic risk and undermines public trust
Argues against centralized AI licensing and attributes industry backlash to excessive doomerism
Noise Level
The timeline
Financial Times interview published
Krishnan articulated the administration's opposition to FDA-style AI regulation and criticized doomer narratives
The full record
Sources & methodology
- — twitter.com Techmeme status 2073066944945910169
- — twitter.com wallstengine status 2073123452832338016
Every claim above traces to these primary items. How we score →
The forecast
Expect executive orders reinforcing sectoral oversight because the administration prioritizes removing barriers to domestic compute scaling over harmonizing with international safety standards.
Forecast, not fact — an editorial estimate we score when this resolves.
That's the complete picture as of — nothing more to know right now. We'll update this page the moment it changes.
Join the Discussion
Discuss this story
Community comments coming in a future update
Be the first to share your perspective. Subscribe to comment.